ArticleProceedings of the National Academy of Sciences of the United States of America2012
A mouse model for HIV-1 entry.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 78 citations in OpenAlex.
- Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes.The Journal of experimental medicine · 2019Trial
- HIV envelope pseudotyped virus- an indispensable tool in HIV research.Virus research · 2026Review
- Priming VRC01-precursor B cells with non-envelope immunogens disfavors boosting with HIV-1 envelope.NPJ vaccines · 2025Article
- Review
- Current methods for detecting and assessing HIV-1 antibody resistance.Frontiers in immunology · 2024Review
- CD4 binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wild-type animals.Science immunology · 2023Article
- Mapping the interplay between NK cells and HIV: therapeutic implications.Journal of leukocyte biology · 2023Review
- Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8Nature communications · 2022Article
- Review
- Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env.Science translational medicine · 2021Article
- Article
- Review
- Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.Journal of virology · 2021Article
- Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.Journal of virology · 2021Article
- Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies.Cell reports · 2021Article
- Neutralizing monoclonal antibodies for COVID-19 treatment and prevention.Biomedical journal · 2021Review
- HIV-1 Envelope Glycosylation and the Signal Peptide.Vaccines · 2021Review
- Multiplexed CRISPR/CAS9-mediated engineering of pre-clinical mouse models bearing native human B cell receptors.The EMBO journal · 2021Article
- Article
- Differential requirements for FcγR engagement by protective antibodies against Ebola virus.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 4 countries.
Funding
Abstract
Passive transfer of neutralizing antibodies against HIV-1 can prevent infection in macaques and seems to delay HIV-1 rebound in humans. Anti-HIV antibodies are therefore of great interest for vaccine design. However, the basis for their in vivo activity has been difficult to evaluate systematically because of a paucity of small animal models for HIV infection. Here we report a genetically humanized mouse model that incorporates a luciferase reporter for rapid quantitation of HIV entry. An antibody's ability to block viral entry in this in vivo model is a function of its bioavailability, direct neutralizing activity, and effector functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.